Angiotensin receptor blockers and myocardial infarction.

BMJ (Clinical research ed.) ·Vol. 329 ·No. 7477 ·2004-11-27 ·Pages 1248-9

Verma S, Strauss M

Abstract

暂无摘要

MeSH Terms

Amlodipine/adverse effects Angiotensin II Type 1 Receptor Blockers/adverse effects,therapeutic use Antihypertensive Agents/adverse effects Benzimidazoles/adverse effects Biphenyl Compounds Humans Hypertension/drug therapy Myocardial Infarction/chemically induced Tetrazoles/adverse effects Truth Disclosure Valine/adverse effects,analogs & derivatives Valsartan

Chemicals

Angiotensin II Type 1 Receptor Blockers Antihypertensive Agents Benzimidazoles Biphenyl Compounds Tetrazoles Amlodipine Valsartan Valine candesartan

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Verma Subodh

Strauss Marty

References (12)

12 references, click to expand

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet. 2002 Mar 23;359(9311):995-1003 PMID: 11937178
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Am Heart J. 2004 Jul;148(1):52-61 PMID: 15215792
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Lancet. 2004 Jun 19;363(9426):2022-31 PMID: 15207952
Is GSK guilty of fraud?
Lancet. 2004 Jun 12;363(9425):1919 PMID: 15194246
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
N Engl J Med. 2001 Sep 20;345(12):851-60 PMID: 11565517
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
N Engl J Med. 2001 Sep 20;345(12):861-9 PMID: 11565518
Blood-pressure reduction and cardiovascular risk in HOPE study.
Lancet. 2001 Dec 22-29;358(9299):2130-1 PMID: 11784631
Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.
BMJ. 2004 Oct 9;329(7470):828 PMID: 15459003
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
J Hypertens. 2003 May;21(5):875-86 PMID: 12714861
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Lancet. 2003 Sep 6;362(9386):772-6 PMID: 13678870
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
Lancet. 2003 Sep 6;362(9386):777-81 PMID: 13678871
Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system.
Circulation. 2004 Jan 6;109(1):8-13 PMID: 14707017

Article Info

Journal

BMJ (Clinical research ed.)

Abbr.

BMJ

ISSN

1756-1833

DOI

10.1136/bmj.329.7477.1248

Published

2004-11-27

Pages

1248-9

Language

English

Region

England

NLM ID

8900488

PMCID

PMC534428

Subset

Corrections

CommentIn

PMID: 15920133

CommentIn

PMID: 15920134

CommentIn

PMID: 15920135

CommentIn

PMID: 15920136

External Links

PubMed source DOI: 10.1136/bmj.329.7477.1248 PMC Full Text View journal details

Analysis Services

Angiotensin receptor blockers and myocardial infarction.

Contact

WeChat Official Account